Healthcare / Medical DevicesShenzhen
$16.25
-0.47 (-2.81%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $113.7M · quality 63.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$7.0B
P/E
60.2x
↑EV/EBITDA
34.3x
↑ROE
10.9%
↑Gross Margin
71.5%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
+9.3%
FCF CAGR
+16.9%
FCF margin
29.6%
FCF / Net income
0.81x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $405.5M · net income $148.9M · FCF $120.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | $405.5M | $405.5M | $375.8M | $326.5M | $336.2M | $284.1M |
| Net Income | $148.9M | $148.9M | $145.6M | $115.4M | $127.1M | $76.8M |
| EBITDA | $167.5M | $167.5M | $153.0M | $121.5M | $127.9M | $293.3M |
| EPS | 0.35 | 0.35 | 0.40 | 0.32 | 0.35 | 0.21 |
| Gross Margin | 71.5% | 71.5% | 70.8% | 69.1% | 67.7% | 100.0% |
| Operating Margin | 38.5% | 38.5% | 37.9% | 33.4% | 33.8% | 100.0% |
| Net Margin | 36.7% | 36.7% | 38.7% | 35.3% | 37.8% | 27.0% |
| Balance Sheet | ||||||
| Current Ratio | 12.71 | 12.71 | — | — | — | — |
| Cash Flow | ||||||
| Free Cash Flow | $120.1M | $120.1M | $113.7M | $71.9M | $127.9M | $64.3M |
| Returns | ||||||
| ROE | 10.9% | 10.9% | 16.7% | 15.9% | 20.9% | — |
| Valuation | ||||||
| P/E | 60.19 | 60.19 | — | — | — | — |
| EV/EBITDA | 34.30 | 34.30 | — | — | — | — |
| P/B | 5.08 | 5.08 | — | — | — | — |
| Growth & Yield | ||||||
| Revenue Growth | 7.9% | 7.9% | 15.1% | -2.9% | — | — |
| EPS Growth | -12.5% | -12.5% | 25.0% | -8.6% | — | — |
| Dividend Yield | 0.6% | 0.6% | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
60.3%
EPS terminal req.
$1.44
Spread vs growth
-72.8%
5Y implied EPS CAGR
37.9%
EPS terminal req.
$1.74
Spread vs growth
-50.4%
10Y implied EPS CAGR
23.2%
EPS terminal req.
$2.81
Spread vs growth
-35.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-36.1%
Start / end P/E
64.1x → 46.4x
EPS bridge
0.40 → 0.35
Residual
+3.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.